Compare Mesoblast Limited (MESO) vs Financial Select Sector SPDR Fund (XLF) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Mesoblast Limited vs Financial Select Sector SPDR Fund — how do they compare? Mesoblast Limited trades at $16.38 (market cap $2.17B), while Financial Select Sector SPDR Fund trades at $56.05. The key difference: Financial Select Sector SPDR Fund is trading nearer its 52-week high, Mesoblast Limited nearer its low. Which is the better fit depends on your goals.
| MESO | XLF | |
|---|---|---|
Market Cap | $2.17B | — |
Sector | Technology | — |
52-Week High | $20.96 | $56.75 |
52-Week Low | $12.88 | $47.80 |
Enterprise Value | $2.17B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MESO trades at $16.63, down 3.98% on the day, with a bullish technical outlook supported by moving averages. The company shows strong revenue growth with Ryoncil generating $115 million in annual revenue, though it remains unprofitable with a net loss of $102 million. Recent developments include positive Phase 3 trial progress and FDA BLA filings for new treatments.
Investment outlook balances promising pipeline progress against significant financial losses. The stock offers growth potential through commercial expansion but carries substantial risk from continued cash burn and regulatory hurdles. Analyst consensus leans bullish with 45% buy ratings, reflecting optimism about the company's transition to commercial-stage operations.
XLF trades at $56.04, down 0.39% on the day, with technical indicators showing a bullish moving average trend but overbought RSI signals. The ETF benefits from strong bank earnings and dividend increases following Fed stress tests. Recent news highlights regional bank strength and AI-driven capital markets activity as key growth drivers.
Outlook remains positive due to robust financial sector performance and potential Fed rate hikes, though geopolitical risks and overbought conditions pose near-term headwinds. The ETF offers exposure to banking sector resilience with a low expense ratio of 0.08%.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Mesoblast Limited
Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.
Read more on MESO →About Financial Select Sector SPDR Fund
The fund generally invests substantially all, but at least 95%, of its total assets in the securities comprising the index. The index includes securities of companies from the following industries: diversified financial services; insurance; banks; capital markets; mortgage real estate investment trusts; consumer finance; thrifts; and mortgage finance. The fund is non-diversified.
Read more on XLF →
